The Parity Paradigm- Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?

Abstract

Over the last decade, there has been increased development and use of oral anticancer medications, which sometimes leads to high cost sharing for patients. Drug parity laws require insurance plans to cover oral anticancer medications with the same cost sharing as intravenous/injected chemotherapy or have a capped limit on out-of-pocket costs. There are currently 36 enacted state laws (plus the District of Columbia) addressing drug parity, but no federal laws. In this policy perspective piece, we discuss the history, opportunities, and limitations of drug parity laws in oncology. We also discuss the implications of provisions of the Affordable Care Act and other proposed policy reforms on financing oral chemotherapy.

Authors

Sheetal M. Kircher Caitlin R. Meeker Halla Nimeiri Daniel M. Geynisman S. Yousuf Zafar Veena Shankaran Jonas de Souza Yu-Ning Wong

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×